2026 Annual Report & Appendix 4E
Filed with ASX · · 99 pages · English
Summary by 6ix AI
The report indicates a decrease in revenue from ordinary activities and an increase in the loss attributable to the owners of the company compared to the previous year. Despite these challenges, the company reported significant growth in core testing revenue and completed a strategic transition to focus on core testing products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Microba Life Sciences Limited on 6ix
Story so far
Earlier from Microba Life Sciences
- 2026 Appendix 4G
- 2026 Corporate Governance Statement
- Genetic Signatures and Microba in Merger Discussions
- Change of Director's Interest Notice - Pasquale Rombola
- Change of Director's Interest Notice - Prof Ian Frazer
Later from Microba Life Sciences
- GSS and MAP agree to Commercial Terms for Merger
- Appointment of Interim Chief Executive Officer
- Change in substantial holding
- Microba launches GI Navigator in Australia and the UK
- Notification of cessation of securities - MAP
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences